Role of Preexisting Disability in Patients Treated With Intravenous Thrombolysis for Ischemic Stroke
Authors:
- Michal KarlinskiMKMichal Karlinski
- Adam KobayashiAKAdam Kobayashi
- Anna CzlonkowskaACAnna Czlonkowska
- Daniel VaclavikDVDaniel Vaclavik
- Miroslav BrozmanMBMiroslav Brozman
- Viktor ŠvigeljVŠViktor Švigelj
- Klara FeketeKFKlara Fekete
- Janika KõrvJKJanika Kõrv
- Aleksandras VilionskisAleksandras Vilionskis
- 1 March 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 45 (3) , 770-775
Abstract
Background and Purpose—: Little is known about the effect of thrombolysis in patients with preexisting disability. Our aim was to evaluate the impact of different levels of prestroke disability on patients’ profile and outcome after intravenous thrombolysis. Methods—: We analyzed the data of all stroke patients admitted between October 2003 and December 2011 that were contributed to the Safe Implementation of Treatments in Stroke–Eastern Europe (SITS-EAST) registry. Patients with no prestroke disability at all (modified Rankin Scale [mRS] score, 0) were used as a reference in multivariable logistic regression. Results—: Of 7250 patients, 5995 (82%) had prestroke mRS 0, 791 (11%) had prestroke mRS 1, 293 (4%) had prestroke mRS 2, and 171 (2%) had prestroke mRS ≥3. Compared with patients with mRS 0, all other groups were older, had more comorbidities, and more severe neurological deficit on admission. There was no clear association between preexisting disability and the risk of symptomatic intracranial hemorrhage. Prestroke mRS 1, 2, and ≥3 were associated with increased risk of death at 3 months (odds ratio, 1.3, 2.0, and 2.6, respectively) and lower chance of achieving favorable outcome (achieving mRS 0–2 or returning to the prestroke mRS; 0.80, 0.41, 0.59, respectively). Patients with mRS ≥3 and 2 had similar vascular profile and favorable outcome (34% versus 29%), despite higher mortality (48% versus 39%). Conclusions—: Prestroke disability does not seem to independently increase the risk of symptomatic intracranial hemorrhage after thrombolysis. Despite higher mortality, 1 in 3 previously disabled patients may return to his/her prestroke mRS. Therefore, they should not be routinely excluded from thrombolytic therapy.Keywords
This publication has 20 references indexed in Scilit:
- Guidelines for the Early Management of Patients With Acute Ischemic StrokeStroke, 2013
- Factors Influencing In-Hospital Delay in Treatment With Intravenous ThrombolysisStroke, 2012
- Intravenous Alteplase in Ischemic Stroke Patients not Fully Adhering to the Current Drug License in Central and Eastern EuropeInternational Journal of Stroke, 2012
- Improved Prediction of Poor Outcome After Thrombolysis Using Conservative Definitions of Symptomatic HemorrhageStroke, 2012
- Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United StatesStroke, 2011
- Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008Cerebrovascular Diseases, 2008
- Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational studyThe Lancet, 2007
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995